Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials.
about
Acupuncture for treatment of irritable bowel syndromePsychological treatments for the management of irritable bowel syndromeBrain imaging and functional gastrointestinal disorders: has it helped our understanding?New directions in brain imaging research in functional gastrointestinal disorders.Systematic review: the effectiveness of hypnotherapy in the management of irritable bowel syndrome.The effects of withdrawing tegaserod treatment in comparison with continuous treatment in irritable bowel syndrome patients with abdominal pain/discomfort, bloating and constipation: a clinical study.Nucleotide supplementation: a randomised double-blind placebo controlled trial of IntestAidIB in people with Irritable Bowel Syndrome [ISRCTN67764449].Occult constipation: faecal retention as a cause of recurrent abdominal pain in children.Fermentable carbohydrates (FODMAPs) exacerbate functional gastrointestinal symptoms in patients with inflammatory bowel disease: a randomised, double-blind, placebo-controlled, cross-over, re-challenge trial.Perilla extract improves gastrointestinal discomfort in a randomized placebo controlled double blind human pilot study.Acupuncture for irritable bowel syndrome: 2-year follow-up of a randomised controlled trial.Managing irritable bowel syndrome: The impact of micro-physiotherapy.Placebo responses in patients with gastrointestinal disordersA randomised controlled trial on hypnotherapy for irritable bowel syndrome: design and methodological challenges (the IMAGINE study).Acupuncture for irritable bowel syndrome: systematic review and meta-analysisLong term benefits of hypnotherapy for irritable bowel syndrome.The placebo effect in irritable bowel syndrome trials: a meta-analysis.Acupuncture treatment in irritable bowel syndromeAcupuncture for irritable bowel syndrome: primary care based pragmatic randomised controlled trial.A neurological approach to biopsychosocial medicine: Lessons from irritable bowel syndrome.Acute exacerbation of pain in irritable bowel syndrome: efficacy of phloroglucinol/trimethylphloroglucinol. A randomized, double-blind, placebo-controlled study.Guidelines on the irritable bowel syndrome: mechanisms and practical management.Moxibustion in the management of irritable bowel syndrome: systematic review and meta-analysisTreating irritable bowel syndrome: overview, perspective and future therapies.Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome.An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome.Benefits from long-term treatment in irritable bowel syndrome.Review article: The rationale for antidepressant therapy in functional gastrointestinal disorders.Effects of anti-secretory factor (ASF) on irritable bowel syndrome (IBS). A double-blind, randomized study.The placebo response in functional bowel disorders: perspectives and putative mechanisms.The rationale, efficacy and safety evidence for tegaserod in the treatment of irritable bowel syndrome.Glucomannan for abdominal pain-related functional gastrointestinal disorders in children: a randomized trial.A meta-analysis of the placebo response in complementary and alternative medicine trials of irritable bowel syndrome.Libertas: a phase II placebo-controlled study of NRL001 in patients with faecal incontinence showed an unexpected and sustained placebo responseBeliefs about GI medications and adherence to pharmacotherapy in functional GI disorder outpatientsPlacebo effects and their determinants in gastrointestinal disorders.A double-blind, placebo-controlled study to assess the effect of a probiotic mixture on symptoms and inflammatory markers in women with diarrhea-predominant IBS.Efficacy of double-coated probiotics for irritable bowel syndrome: a randomized double-blind controlled trial.Effects of linseeds on the symptoms of irritable bowel syndrome: a pilot randomised controlled trial.Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome.
P2860
Q24197693-954C066C-5997-4DAA-B29C-0DB3974021D3Q24241516-33F4424A-2A02-4EC7-90B0-83280D71F08BQ30942661-544CAAD6-51DE-4316-834B-0DE2A2A9059CQ31049096-9A1FC483-8210-464A-AD21-808F5C3A97D7Q33254446-2205D38D-057E-4FEE-B2D8-B68A4F8CF437Q33431815-E351E546-8D3D-4D6C-AA2F-3D42AE81803CQ33435380-54B2E4D5-69A2-4CA4-9493-A396CDB94C4BQ33460442-C19B0DF2-1919-4C9B-85EE-82384156C730Q33470528-0F938764-2480-4003-A364-0F28FB4C2112Q33687137-A100CBA0-83A7-4F00-9240-7D8F604D716EQ33785465-8A420C5B-19C8-4A64-B9C5-364C374E4151Q34048040-FB4ABB66-242A-455C-B90B-28CA2952329AQ34098616-F72B56E3-7A1E-4A51-9740-583D6711FBDEQ34106923-251507B8-9E8C-473B-81DF-7B0F0F208A9EQ34266907-9F7EA043-C47C-40FF-ADD3-3D03D0F9769AQ34271499-01283E4B-79DA-4608-8BFE-EA495D31517AQ34421382-6005A581-4C43-4036-BE60-983DC1B176C9Q34449406-0CE52C91-CCCC-429F-9DF4-56BC8555F968Q34457042-A5EB1149-5236-4253-A295-3CBBF4DF3702Q34589513-C0714453-AD6E-4F6D-AC2B-C750E67E6814Q34619848-4A6280A5-12D8-4D31-9E4E-9D5CC2F13083Q34626602-4A6B4693-D068-44D2-8585-3E298D17E726Q34656427-5E33FBE7-D214-4BE9-95C3-5784F73D8FF6Q35047051-98892856-CFB4-4F06-91B3-52180A160DCCQ35216885-231581E9-0F3D-4884-8062-5B1515773ED8Q35595584-EBA04058-4810-4EDF-A953-CBBB0838EA9AQ35681391-3F0078EA-A80F-46E8-A805-D7520FD24C4DQ35758323-56E53EAC-7095-4CAC-8F8B-8334EB8ABF7AQ36122008-89F3DA57-07B1-40D7-B28A-48F3AE544E35Q36139392-3DE5C954-FCDC-466F-BB5B-68F727434BF6Q36407290-25FAE5DC-5678-46EC-ABD4-E3298008F360Q36871992-9B49C6B7-C02A-4A13-937A-070B4E8F0DD8Q36886282-4B87B1B7-C682-4115-90EA-F59EEA8C5252Q36901639-674134AE-B951-47FB-A346-B21E9BD30F98Q37313060-C7A18A53-4720-4E83-AC27-EA9E944154A3Q38551120-43A69211-0B32-4BE2-9FC3-A5A52E683496Q38921708-8771A92E-321C-4F54-B2EA-6C514394129FQ39172677-93AB19D4-BF13-4B48-AFBC-A2F10433A9BBQ39246448-3F1D2F6D-1EE6-417C-9148-02A72C91F892Q39331829-7689310E-F2C6-4592-993E-F18DBFD1CDCC
P2860
Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials.
description
1999 nî lūn-bûn
@nan
1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Problems and challenges in the ...... erience from published trials.
@ast
Problems and challenges in the ...... erience from published trials.
@en
type
label
Problems and challenges in the ...... erience from published trials.
@ast
Problems and challenges in the ...... erience from published trials.
@en
prefLabel
Problems and challenges in the ...... erience from published trials.
@ast
Problems and challenges in the ...... erience from published trials.
@en
P1476
Problems and challenges in the ...... erience from published trials.
@en
P2093
Spiller RC
P304
P356
10.1016/S0002-9343(99)00086-8
P407
P577
1999-11-01T00:00:00Z